Your session is about to expire
← Back to Search
Cancer Vaccine + GM-CSF and Cyclophosphamide for Triple Negative Breast Cancer
Study Summary
This trial is testing a vaccine made from a person's white blood cells mixed with tumor proteins, given with sargramostim (GM-CSF) and cyclophosphamide, to see if it can prevent the recurrence of stage 1-3 triple negative breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am currently breastfeeding.You have had a bad reaction to GM-CSF before.My breast cancer was surgically removed, is not spread, and tests negative for ER, PR, and HER2.I do not have any severe illnesses or social situations that would stop me from following the study's requirements.I have used trastuzumab or other HER2-targeted treatments.I am a woman who can have children and do not plan to use birth control.I am 18 years old or older.I have not had or been treated for another cancer in the last 5 years.I haven't used PD-1 or PD-L1 inhibitors in the last 3 months.I am female.I am not currently receiving any experimental drugs or other cancer treatments.My cancer has returned or spread to other parts of my body.I finished my last breast cancer treatment between 3 and 18 months ago.I have an autoimmune disease treated within the last 30 days.I am HIV positive and currently on antiretroviral therapy.I haven't taken steroids or immune-modulators in the last 7 days.
- Group 1: Arm I (FRalpha peptide vaccine, sargramostim)
- Group 2: Arm II (placebo, sargramostim)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What adverse effects have been reported with administering the Multi-epitope Folate Receptor Alpha Peptide Vaccine?
"Our experts at Power rated the safety of Multi-epitope Folate Receptor Alpha Peptide Vaccine a 2, as data collected from Phase 2 trials demonstrate its relative security yet there is no evidence for efficacy."
Are there any records of other experiments involving Multi-epitope Folate Receptor Alpha Peptide Vaccine?
"In 1997, Multi-epitope Folate Receptor Alpha Peptide Vaccine was first researched by City of Hope Comprehensive Cancer Center. Since then, 1850 studies have been completed. Presently 865 clinical trials are actively recruiting participants across the USA, with a notable concentration in Boston ma."
In how many distinct areas is this clinical experiment being managed?
"This medical study has 11 unique sites of operation, including the Massachusetts General Hospital Cancer Center in Boston, Ochsner Medical Center Jefferson in New Orleans, and Mayo Clinic Arizona in Scottsdale. Additional locations are available as well."
What is the typical purpose for administering Multi-epitope Folate Receptor Alpha Peptide Vaccine?
"The Multi-epitope Folate Receptor Alpha Peptide Vaccine is typically used to treat the proliferation of lung cancer. In some cases, it has been employed as an intervention for lymphoma, Hodgkin's disease, bone marrow transplantation and multiple sclerosis."
How many participants have joined this research endeavor?
"Unfortunately, this research is currently not accepting applicants. This experiment was first posted in March of 2017 and last updated on September 23rd 2022. Fortunately, there are 4,600 studies investigating breast cancer and 865 experiments exploring the Multi-epitope Folate Receptor Alpha Peptide Vaccine that are actively recruiting patients at present."
Are recruitment efforts still ongoing for this clinical experiment?
"At the present moment, this clinical trial is not actively recruiting. Initially posted on March 31st 2017 and last updated on September 23rd 2022, people seeking to participate in medical research should consider one of the 4600 trials enrolling patients with breast cancer or 865 studies for Multi-epitope Folate Receptor Alpha Peptide Vaccine which are currently open."
Share this study with friends
Copy Link
Messenger